Point of Care Diagnostic test for Molecular Subtyping of Breast Cancer (PoCBreCa Study)

乳腺癌分子亚型的床旁诊断检测（PoCBreCa）研究 项目摘要 低收入和中等收入国家（LMIC）的乳腺癌发病率正在迅速上升。尽管如此， 在这些国家，人们对乳腺癌分子亚型的流行病学知之甚少， 缺乏免疫组织化学（IHC）的设施，资源和人员，目前的黄金标准 乳腺癌的分子亚型创新的战略，结合联合收割机纳米技术，光子学， 小型化和手机网络开发新的技术和工具包可以克服这些限制 并增加LMIC中乳腺癌分子亚型的可用性。 分子分型的增加将使流行病学研究的决定因素 LMIC中乳腺癌分子亚型发病率的长期趋势， 产生了相互矛盾的结果。它还将使临床医生能够选择乳腺癌治疗，预测乳腺癌的发生率， 反应和预后。我们建议在这个项目中开发的工具包将产生定量结果 这将为基于定量水平的精准医学开辟新的研究和治疗机会 激素受体及其决定因素与生殖系和体细胞、遗传和表观遗传的关系 变化. 在这个项目中，来自马里兰州医学院、巴尔的摩和康奈尔大学的研究人员 生物伦理学和研究中心，以及尼日利亚的伊巴丹大学 共同开发和试点测试用于乳腺肿瘤分子亚型的护理点诊断试剂盒， 将其与IHC进行比较，以克服当前的挑战并为乳腺癌开辟新的机会 research.

Point of Care Diagnostic test for Molecular Subtyping of Breast Cancer (PoCBreCa) Study Project Summary The incidence of breast cancer in low and middle-income countries (LMIC) is rising rapidly. Despite this, very little is known about the epidemiology of molecular subtypes of breast cancer in these countries because of lack of facilities, resources and personnel for immunohistochemistry (IHC), the current gold standard for molecular subtyping of breast cancer. Innovative strategies that combine nanotechnology, photonics, miniaturization and cell phone networks to develop new technologies and kits can overcome these limitations and increase availability of molecular subtyping of breast cancer in LMIC. Increased availability of molecular subtyping will enable epidemiological research into the determinants and secular trend in the incidence of molecular subtypes of breast cancer in LMIC where previous studies have yielded conflicting results. It will also empower clinicians in their choice of breast cancer treatment, prediction of response and prognosis. The kits that we propose to develop in this project will generate quantitative results which will open new research and treatment opportunities for precision medicine based on quantitative levels of hormone receptors, its determinants and associations with germline and somatic, genetic and epigenetic variations. In this project, researchers at University of Maryland School of Medicine, Baltimore and Cornell University in the United States, and Center for Bioethics and Research, and the University of Ibadan in Nigeria work together to develop and pilot-test a point of care diagnostic kit for molecular subtyping of breast tumors and compare it to IHC in order to overcome current challenges and open new opportunities for breast cancer research.